Logo image of ACRS

ACLARIS THERAPEUTICS INC (ACRS) Stock Fundamental Analysis

NASDAQ:ACRS - Nasdaq - US00461U1051 - Common Stock - Currency: USD

1.38  0 (0%)

After market: 1.38 0 (0%)

Fundamental Rating

3

ACRS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. The financial health of ACRS is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ACRS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ACRS has reported negative net income.
ACRS had a negative operating cash flow in the past year.
ACRS had negative earnings in each of the past 5 years.
ACRS had a negative operating cash flow in each of the past 5 years.
ACRS Yearly Net Income VS EBIT VS OCF VS FCFACRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of ACRS (-59.94%) is worse than 66.67% of its industry peers.
The Return On Equity of ACRS (-84.90%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -59.94%
ROE -84.9%
ROIC N/A
ROA(3y)-46.3%
ROA(5y)-49.43%
ROE(3y)-61.73%
ROE(5y)-73.31%
ROIC(3y)N/A
ROIC(5y)N/A
ACRS Yearly ROA, ROE, ROICACRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

ACRS has a Gross Margin (17.43%) which is in line with its industry peers.
ACRS's Gross Margin has improved in the last couple of years.
ACRS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 17.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.86%
GM growth 5Y34.1%
ACRS Yearly Profit, Operating, Gross MarginsACRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

ACRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACRS has more shares outstanding
Compared to 5 years ago, ACRS has more shares outstanding
ACRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACRS Yearly Shares OutstandingACRS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ACRS Yearly Total Debt VS Total AssetsACRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -4.58, we must say that ACRS is in the distress zone and has some risk of bankruptcy.
ACRS has a worse Altman-Z score (-4.58) than 61.62% of its industry peers.
ACRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.58
ROIC/WACCN/A
WACC9.5%
ACRS Yearly LT Debt VS Equity VS FCFACRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

ACRS has a Current Ratio of 3.99. This indicates that ACRS is financially healthy and has no problem in meeting its short term obligations.
ACRS's Current ratio of 3.99 is fine compared to the rest of the industry. ACRS outperforms 63.13% of its industry peers.
A Quick Ratio of 3.99 indicates that ACRS has no problem at all paying its short term obligations.
ACRS has a better Quick ratio (3.99) than 64.65% of its industry peers.
Industry RankSector Rank
Current Ratio 3.99
Quick Ratio 3.99
ACRS Yearly Current Assets VS Current LiabilitesACRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

ACRS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.80%.
The Revenue for ACRS has decreased by -40.09% in the past year. This is quite bad
The Revenue has been growing by 34.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-20.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4950%
Revenue 1Y (TTM)-40.09%
Revenue growth 3Y40.43%
Revenue growth 5Y34.65%
Sales Q2Q%-47.58%

3.2 Future

The Earnings Per Share is expected to grow by 6.00% on average over the next years.
Based on estimates for the next years, ACRS will show a very strong growth in Revenue. The Revenue will grow by 48.98% on average per year.
EPS Next Y60.48%
EPS Next 2Y22.42%
EPS Next 3Y11.79%
EPS Next 5Y6%
Revenue Next Year-55.21%
Revenue Next 2Y53.49%
Revenue Next 3Y24.18%
Revenue Next 5Y48.98%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ACRS Yearly Revenue VS EstimatesACRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
ACRS Yearly EPS VS EstimatesACRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACRS. In the last year negative earnings were reported.
Also next year ACRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRS Price Earnings VS Forward Price EarningsACRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRS Per share dataACRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.42%
EPS Next 3Y11.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACRS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACLARIS THERAPEUTICS INC

NASDAQ:ACRS (5/1/2025, 4:30:01 PM)

After market: 1.38 0 (0%)

1.38

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)05-13 2025-05-13/bmo
Inst Owners82.79%
Inst Owner Change0.35%
Ins Owners2.53%
Ins Owner Change15.6%
Market Cap148.93M
Analysts84.62
Price Target10.4 (653.62%)
Short Float %3.87%
Short Ratio4.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1070.85%
Min EPS beat(2)-1788.67%
Max EPS beat(2)-353.03%
EPS beat(4)2
Avg EPS beat(4)-524%
Min EPS beat(4)-1788.67%
Max EPS beat(4)28.07%
EPS beat(8)6
Avg EPS beat(8)-245.81%
EPS beat(12)10
Avg EPS beat(12)-157.6%
EPS beat(16)11
Avg EPS beat(16)-126.75%
Revenue beat(2)1
Avg Revenue beat(2)144.13%
Min Revenue beat(2)-40.15%
Max Revenue beat(2)328.42%
Revenue beat(4)3
Avg Revenue beat(4)102.37%
Min Revenue beat(4)-40.15%
Max Revenue beat(4)328.42%
Revenue beat(8)6
Avg Revenue beat(8)167.27%
Revenue beat(12)8
Avg Revenue beat(12)221.63%
Revenue beat(16)10
Avg Revenue beat(16)165.84%
PT rev (1m)7.37%
PT rev (3m)27.5%
EPS NQ rev (1m)-17.5%
EPS NQ rev (3m)-21.55%
EPS NY rev (1m)-18.42%
EPS NY rev (3m)-30.48%
Revenue NQ rev (1m)0.38%
Revenue NQ rev (3m)-32.96%
Revenue NY rev (1m)-42.1%
Revenue NY rev (3m)-45.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.96
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 0.96
EV/EBITDA N/A
EPS(TTM)-1.51
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0.17
BVpS1.44
TBVpS1.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.94%
ROE -84.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 17.43%
FCFM N/A
ROA(3y)-46.3%
ROA(5y)-49.43%
ROE(3y)-61.73%
ROE(5y)-73.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.86%
GM growth 5Y34.1%
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4452.42%
Cap/Sales 191.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.99
Quick Ratio 3.99
Altman-Z -4.58
F-Score2
WACC9.5%
ROIC/WACCN/A
Cap/Depr(3y)1560.12%
Cap/Depr(5y)949.63%
Cap/Sales(3y)66.06%
Cap/Sales(5y)41.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4950%
EPS Next Y60.48%
EPS Next 2Y22.42%
EPS Next 3Y11.79%
EPS Next 5Y6%
Revenue 1Y (TTM)-40.09%
Revenue growth 3Y40.43%
Revenue growth 5Y34.65%
Sales Q2Q%-47.58%
Revenue Next Year-55.21%
Revenue Next 2Y53.49%
Revenue Next 3Y24.18%
Revenue Next 5Y48.98%
EBIT growth 1Y39.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.73%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.37%
OCF growth 3YN/A
OCF growth 5YN/A